CONTENTS:
- Evaluating how has care been affected by the Ontario COVID-19 Opioid Agonist Treatment Guidance: Patients' and prescribers' experiences with changes in unsupervised dosing. Corace K., Suschinsky K., Wyman J., Leece P., Cragg S., Konefal S., et al., art. 103573.
- From strong leadership to active community engagement: Effective resistance to illegal coca crops in Afro-Colombian collective territories. Lobo I.D., Vélez M.A., art. 103579.
- An on-site community-based model for hepatitis C screening, diagnosis, and treatment among people who inject drugs in Kerman, Iran: The Rostam study. Mirzazadeh A., Hosseini-Hooshyar S., Shahesmaeili A., Sharafi H., Shafiei M., Zarei J., et al., art. 103580.
- No party, no drugs? Use of stimulants, dissociative drugs, and GHB/GBL during the early COVID-19 pandemic. Bendau A., Viohl L., Petzold M.B., Helbig J., Reiche S., Marek R., et al., art. 103582.
- Direct democracy and the adoption of recreational marijuana legalization in the United States, 2012-2019. Vann Jr B., art. 103583.
- Latent patterns of polysubstance use among people who use opioids: A systematic review. Karamouzian M., Pilarinos A., Hayashi K., Buxton J.A., Kerr T., art. 103584.
- Cannabis industry lobbying in the Colorado state legislature in fiscal years 2010-2021. Rotering T., Apollonio D.E., art. 103585.
- Interventions to increase linkage to care and adherence to treatment for hepatitis C among people who inject drugs: A systematic review and practical considerations from an expert panel consultation. Schwarz T., Horvath I., Fenz L., Schmutterer I., Rosian-Schikuta I., Mardh O., art. 103588.
- The state of science on including inhalation within supervised consumption services: A scoping review of academic and grey literature. Gehring N.D., Speed K.A., Launier K., O'Brien D., Campbell S., Hyshka E., art. 103589.
- Changes in retrospectively recalled alcohol use pre, during and post alcohol sales prohibition during COVID pandemic in Botswana. Maphisa J.M., Mosarwane K., art. 103590.
- Methadone exposures reported to poison control centers in the United States following the COVID-19-related loosening of federal methadone regulations. Welsh C., Doyon S., Hart K., art. 103591.
- Characterizing stimulant overdose: A qualitative study on perceptions and experiences of "overamping". Mansoor M., McNeil R., Fleming T., Barker A., Vakharia S., Sue K., et al., art. 103592.
- Stigma and ART initiation among people with HIV and a lifetime history of illicit drug use in Saint-Petersburg, Russia-A prospective cohort analysis. Vetrova M., Lodi S., Rateau L., Patts G., Blokhina E., Palatkin V., et al., art. 103600.
- Characterizing safer supply prescribing of immediate release hydromorphone for individuals with opioid use disorder across Ontario, Canada. Young S., Kolla G., McCormack D., Campbell T., Leece P., Strike C., et al., art. 103601.
- Correlates of concurrent use of stimulants and opioids among people who access harm reduction services in British Columbia, Canada: Findings from the 2019 Harm Reduction Client Survey. Lukac C.D., Steinberg A., Papamihali K., Mehta A., Lock K., Buxton J.A., art. 103602.
- The details of decriminalization: Designing a non-criminal response to the possession of drugs for personal use. Greer A., Bonn M., Shane C., Stevens A., Tousenard N., Ritter A., art. 103605.
- Youth drinking in decline: What are the implications for public health, public policy and public debate? Holmes J., Fairbrother H., Livingston M., Meier P.S., Oldham M., Pennay A., et al., art. 103606.
- Examining reactions to smoking and COVID-19 risk messages: An experimental study with people who smoke. Massey Z.B., Duong H.T., Churchill V., Popova L., art. 103607.
- COVID-19 economic impact payments and opioid overdose deaths. Sprague J.E., Yeh A.B., Lan Q., Vieson J., McCorkle M., art. 103608.
- 'Not just one box that you tick off' - Deconstructing the hepatitis C care cascade in the interferon-free direct acting antiviral era from the client perspective. Marshall A.D., Rance J., Grebely J., Treloar C., art. 103610.
- Rapid and accurate etizolam detection using surface-enhanced Raman spectroscopy for community drug checking. Gozdzialski L., Rowley A., Borden S.A., Saatchi A., Gill C.G., Wallace B., et al., art. 103611.
- Is approving esketamine as an antidepressant for treatment resistant depression associated with recreational use and risk perception of ketamine? Results from a longitudinal and cross-sectional survey in nightlife attendees. Grabski M., Waldron J., Freeman T.P., van Laar M., Curran H.V., art. 103612.
- Perceived availability and carriage of take-home naloxone and factors associated with carriage among people who inject drugs in England, Wales and Northern Ireland. Spring C., Croxford S., Ward Z., Ayres R., Lord C., Desai M., et al., art. 103615.
- Tobacco use in people living with HIV: The need for complementary descriptive data to see beyond the smoke screen. Marcellin F., Zucman D., Ramier C., Lotto M., Miailhes P., Piroth L., et al., art. 103616.
- Medication for opioid use disorder in the Arab World: A systematic review. Alawa J., Muhammad M., Kazemitabar M., Bromberg D.J., Garcia D., Khoshnood K., et al., art. 103617.